Table 3.
Univariate | Multivariate | |||
---|---|---|---|---|
Variable | OR | (95% CI) | OR | (95% CI) |
Age at start of adjuvant therapy (yrs) | 0.99 | (0.94–1.04) | ||
Stage of Disease | ||||
I or II | 1 (ref) | 1(ref) | ||
III | 23.33 | (4.86–179.29) ** | 22.64 | (3.59–256.25) ** |
Lymph Node Status | ||||
pN negative | 1 (ref) | |||
pN positive | 6.79 | (1.73–34.82) ** | ||
Tumor Size (at Diagnosis) § | ||||
pT1 or pT2 | 1 (ref) | |||
pT3 or pT4 | - | - | ||
Tumor Histology | ||||
Ductal carcinoma | 1 (ref) | |||
Lobular carcinoma | 0.58 | (0.03–6.51) | ||
Other | 1.16 | (0.04–30.63) | ||
Histologic Grade | ||||
1 | 1 (ref) | |||
2 | 0.56 | (0.02–16.14) | ||
3 | 1.00 | (0.04–27.00) | ||
Ki-67 | ||||
<20% | 1 (ref) | |||
≥20% | 0.94 | (0.27–3.30) | ||
ER | ||||
Negative | 1 (ref) | |||
Positive | 0.97 | (0.27–3.62) | ||
PgR | ||||
Negative | 1 (ref) | |||
Positive | 0.96 | (0.29–3.17) | ||
Adjuvant Chemotherapy § | ||||
Anthracyclines and taxanes | 1 (ref) | |||
Taxanes only | 5.33 | (0.08–46.61) | ||
Anthracyclines only | 0.76 | (0.10–4.32) | ||
Other (endocrine therapy, CMF, vinorelbine) | - | - | ||
BMI at start of Adjuvant Chemotherapy | 1.21 | (1.03–1.45) * | 1.25 | (0.99–1.65) |
HDAC6 ¥ | 16.49 | (2.58–164.10) ** | 32.78 | (2.65–973.27) * |
HDAC6 † | 2.55 | (1.37–5.47) | 3.20 | (1.38–9.91) |
WNT4 ¥ | 0.93 | (0.55–1.54) | ||
BMPR2 ¥ | 7.38 | (1.19–64.35) * | ||
PALB2 ¥ | 0.72 | (0.15–3.16) | ||
PARP1 ¥ | 2.55 | (0.73–10.20) | 0.157 |
OR: odds ratio; CI: confidence interval; ER: estrogen receptor; PgR: progesterone receptor; BMI: body mass index; CMF: Cyclophosphamide, Methotrexate, Fluorouracil. ** p-value < 0.01; * p-value < 0.05. § Due to the presence of zero cells, the ORs were not computed. ¥ Reported as log2 transformed variable. † Reported as log2 transformed variable and multiplied by 3. The associated odds ratio then is for a 1/3-unit increase in log2 transformed HDAC6. The p-value is the same as log2 transformed only variable.